Billionaire Seth Klarman's Biotech Stock Picks
Billionaire Seth Klarman is a notorious investor who despite his uncoventional approaches always managed to achieve high returns.
Theseus Pharmaceuticals Inc. (THRX)
Market is closed
News
- First
- << Previous
- 11 - 20
- Next >>
Pitney Bowes Inc. (PBI) and Theravance Inc (THRX)'s Stakes Further Rise In Iridian's Portfolio
In two recently amended filings David Cohen and Harold Levy's Iridian Asset Management has disclosed further increasing its passive stakes in Theravance Inc (NASDAQ:THRX) to 12.40 million shares from...
Pitney Bowes Inc. (PBI), Graphic Packaging Holding Company (GPK), Theravance Inc (THRX): Iridian Asset Management’s Latest Moves
David Cohen and Harold Levy’s Iridian Asset Management filed several 13G forms with the U.S. Securities and Exchange Commission on Thursday, disclosing an increase in numerous positions.
Seth Klarman’s Baupost Group Continues to Bet on Tech
On Wednesday, May 14th, Seth Klarman’s Baupost Group, presented its Form 13F Filing for the first quarter of 2014 at the U.S. Securities and Exchange Commission.
Baupost Group and Seth Klarman Are Fond of Micron Technology, Inc. (MU), Theravance Inc (THRX) & Others
Baupost Group, managed by Seth Klarman, in a new 13F filing, reported the holdings from its equity portfolio for the fourth quarter.
Relvar Ellipta: GlaxoSmithKline and Theravance’s Drug for Respiratory Diseases
Relvar Ellipta: Over the past few days, research-based pharmaceutical GlaxoSmithKline plc (ADR) (NYSE:GSK) and biopharmaceutical company Theravance Inc (NASDAQ:THRX)’s Relvar Ellipta has been in the...
GlaxoSmithKline plc (ADR) (GSK), Theravance Inc (THRX), Teva Pharmaceutical Industries Ltd (ADR) (TEVA): Could a Pair of Respiratory Disease Treatments Save This Big Pharma?
GlaxoSmithKline plc (ADR) (NYSE:GSK) and its partner Theravance Inc (NASDAQ:THRX) recently scored a second victory in their quest to treat chronic obstructive pulmonary disease, commonly abbreviated...
Regeneron Pharmaceuticals Inc (REGN), Viropharma Inc (VPHM): Sanofi SA (ADR) (SNY)'s Interest Sparks Biotech Stocks in a Huge Week for Investors
Looking for the best-performing sector in this year's big market rally? It may just be the biotech sector, which has erupted with astronomical gains in 2013.
Theravance Inc (THRX), GlaxoSmithKline plc (ADR) (GSK): Time to Bet on This Biotech Spinoff?
There hasn't been a dull moment for investors of Theravance Inc (NASDAQ:THRX) since the company submitted an NDA for COPD/asthma drug BREO before the Food and Drug Administration in 2012.
Theravance Inc (THRX): Are Hedge Funds Right About This Stock?
At the moment, there are many indicators investors can use to analyze stocks. Some of the most under-the-radar are hedge fund and insider trading activity.
- First
- << Previous
- 11 - 20
- Next >>
Billionaire Hedge Funds
